Nymox Pharmaceutical Corp RSI
Was ist das RSI von Nymox Pharmaceutical Corp?
RSI von Nymox Pharmaceutical Corp ist 30.58
Was ist die Definition von RSI?
Der relative Stärke-Index (RSI 14) ist ein Momentumindikator, der die Größe von Gewinnen und Verlusten über einen bestimmten Zeitraum vergleicht, um die Geschwindigkeit und die Änderung von Preisbewegungen eines Wertpapiers zu messen.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Nymox Pharmaceutical Corp
Was macht Nymox Pharmaceutical Corp?
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Unternehmen mit rsi ähnlich Nymox Pharmaceutical Corp
- Allena Pharmaceuticals Inc hat RSI von 30.56
- WINDMILL hat RSI von 30.56
- Capitan Investment hat RSI von 30.56
- Lacroix SA hat RSI von 30.56
- Basler Aktiengesellschaft hat RSI von 30.57
- Lumos Diagnostics hat RSI von 30.57
- Nymox Pharmaceutical Corp hat RSI von 30.58
- Impro Precision Industries hat RSI von 30.59
- E.W. Scripps hat RSI von 30.59
- Altura Mining hat RSI von 30.59
- Beijing Yuanliu Hongyuan Electronic Technology Co hat RSI von 30.59
- Cambridge Technology Enterprises hat RSI von 30.59
- Alibaba Health Information Tech hat RSI von 30.59